Study of CeftazidimeAvibactam and Fosfomycin Use in Adults with Carbapenem-resistant Enterobacterales Infections

What this Trial Is About

This research investigates how the drugs ceftazidimeavibactam CAZAVI and fosfomycin FOS, alone or combined, work in adult patients with infections caused by carbapenem-resistant Enterobacterales CRE. These infections are serious and can affect survival, especially in high-risk situations like pneumonia or in patients with kidney problems. The study aims to find how well these drugs reach effective levels in the body and their impact on patient outcomes. Participants receive treatment with CAZAVI alone or with CAZAVI plus FOS for at least 48 hours as part of their care for confirmed CRE infections. The study does not assign specific treatments but observes patients receiving these medications in different ways. Researchers monitor drug levels and clinical responses during and shortly after treatment. During the study, patients are evaluated for how well the drugs reach target levels within 48 to 72 hours of starting treatment. Secondary assessments include changes in organ function scores, inflammation markers, infection clearance, relapse or reinfection rates, and overall survival up to three months. Data collection involves clinical and laboratory measures to understand treatment effectiveness and safety over time.

PK/PD Relationship of CAZ/AVI and FOS in the Treatment of Patients With Infections Due to CRE